Goldman Sachs
CRL icon

Goldman Sachs’s Charles River Laboratories CRL Stock Holding History

Goldman Sachs’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,700
Closed -$243K – 6783
2017
Q1 		$243K Buy
+2,700
New +$229K ﹤0.01% 5598
2013
Q3 		– Sell
-50,000
Closed -$2.05M – 6572
2013
Q2 		$2.05M Buy
+50,000
New +$2.14M ﹤0.01% 3706

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs's CRL Position: Q1 2026 in Review

Goldman Sachs increased its Charles River Laboratories (CRL) stake by 31% in Q1 2026, buying an estimated $18M and bringing the position to 414,728 shares worth $71.5M. The position accounts for 0.01% of the portfolio, ranked #1282.

Goldman Sachs first reported a position in CRL in Q2 2013 and has held it in 52 quarters since. The position peaked at $150M in Q1 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Goldman Sachs held 414,728 shares of Charles River Laboratories worth $71.5M as of Q1 2026.
  • Goldman Sachs bought 97,109 Charles River Laboratories shares in Q1 2026, an estimated $18M.
  • Charles River Laboratories made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1282 holding.
  • Goldman Sachs first reported a position in Charles River Laboratories in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Charles River Laboratories position peaked at $150M in Q1 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.